ASTS
AST SpaceMobile, Inc.
ASTS lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow, though they disagree widely on how much.
MSTR
Strategy Inc
There isn't enough reported data to score MSTR yet.
ASTS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ASTS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
MSTR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Under pressure | |
| Strong |
MSTR's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
ASTS PE Valuation
ASTS has no meaningful PE right now: it lost money over the past year.
MSTR PE Valuation
MSTR has no meaningful PE right now: it lost money over the past year.
ASTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ASTS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
MSTR Forward outlook
There aren't enough analyst estimates for MSTR to show an outlook.
ASTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.15 | -$0.91 |
| Q2 2026 | -$2.16 | -$0.27 |
| Q1 2026 | -$1.80 | +$0.19 |
| Q4 2025 | -$1.34 | +$0.61 |
| Q3 2025 | -$1.24 | +$0.88 |
| Q2 2025 | -$1.89 | -$0.64 |
| Q1 2025 | -$1.99 | -$1.01 |
| Q4 2022 | -$0.58 | -$0.21 |
ASTS has the edge over MSTR on earnings, with more consistent year-over-year improvement.
MSTR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$57.71 | -374% |
| Q2 2026 | -$94.04 | -960% |
| Q1 2026 | -$36.99 | -$14.75 |
| Q4 2025 | -$15.23 | -$9.17 |
| Q3 2025 | $21.07 | +$23.35 |
| Q2 2025 | $10.93 | +$12.50 |
| Q1 2025 | -$22.24 | -$21.39 |
| Q4 2024 | -$6.06 | -330% |
MSTR has swung to a loss: it lost $57.71 per share over the past year, after a profit the year before.
ASTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.3M | +187% |
| Q2 2026 | $31.5M | +2627% |
| Q1 2026 | $14.7M | +1952% |
| Q4 2025 | $54.3M | +2731% |
| Q3 2025 | $14.7M | +1240% |
| Q2 2025 | $1.2M | +28% |
| Q1 2025 | $718K | +44% |
| Q3 2022 | $4.2M | +70% |
ASTS has the edge over MSTR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -415% | +694 points |
| Q2 2026 | -948% | +10744 points |
| Q1 2026 | -1686% | +7083 points |
| Q4 2025 | -175% | +2446 points |
| Q3 2025 | -1109% | +4850 points |
| Q2 2025 | -11692% | -4693 points |
| Q1 2025 | -8769% | +2331 points |
| Q4 2024 | -2621% | N/A |
ASTS's operating margin was −415% last quarter, up 694 points from the same quarter a year ago.
MSTR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $125.4M | -2.5% |
| Q2 2026 | $122.4M | +6.9% |
| Q1 2026 | $124.3M | +12% |
| Q4 2025 | $123M | +1.9% |
| Q3 2025 | $128.7M | +11% |
| Q2 2025 | $114.5M | +2.7% |
| Q1 2025 | $111.1M | -3.6% |
| Q4 2024 | $120.7M | -3% |
MSTR's revenue has picked up after five years of holding roughly level: $125M last quarter, down 2.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16671% | +13648 points |
| Q2 2026 | -6808% | -19064 points |
| Q1 2026 | -11642% | -6310 points |
| Q4 2025 | -14185% | -13343 points |
| Q3 2025 | 3023% | +3396 points |
| Q2 2025 | 12256% | +12436 points |
| Q1 2025 | -5331% | -5155 points |
| Q4 2024 | -842% | -808 points |
MSTR has the edge over ASTS on profitability, with a higher operating margin.
ASTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$464.2M | -$161.4M |
| Q2 2026 | -$694.8M | -$341.1M |
| Q1 2026 | -$309.7M | -$160.7M |
| Q4 2025 | -$330.7M | -$220.3M |
| Q3 2025 | -$302.9M | -$239.1M |
| Q2 2025 | -$353.6M | -$315.3M |
| Q1 2025 | -$149M | -$61.3M |
| Q4 2024 | -$110.5M | -$63.2M |
ASTS has burned cash in almost every quarter: −$1.8B over the past year, against −$916M the year before.
MSTR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4M | +$15.1M |
| Q2 2026 | -$5.9M | +$31.1M |
| Q1 2026 | $13M | +$18.2M |
| Q4 2025 | -$22.2M | -$4.6M |
| Q3 2025 | -$11.1M | +$30.3M |
| Q2 2025 | -$37M | -$13M |
| Q1 2025 | -$5.1M | -119% |
| Q4 2024 | -$17.6M | -2204% |
MSTR has the edge over ASTS on cash flow, with more consistent year-over-year improvement.
ASTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +10% | +27.3M shares |
| 3 years | +235% | +211M shares |
| 5 years | +480% | +248M shares |
| Available history | +944% | +271M shares |
ASTS has the edge over MSTR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
MSTR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +21% | +75.5M shares |
| 1 year | +36% | +113M shares |
| 3 years | +201% | +286M shares |
| 5 years | +328% | +328M shares |
| Available history | +314% | +325M shares |
MSTR has 428M diluted shares, up 36% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | $744,000 |
| Q3 2020 | $60.6M |
| Q2 2020 | $11.1M |
| Q1 2020 | $50.7M |
ASTS Net Leverage
ASTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MSTR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 0.7x | Very low |
| Q2 2025 | 1.2x | Healthy |
| Q3 2020 | -5.2x | Net Cash |
| Q2 2020 | -11.9x | Net Cash |
| Q1 2020 | -17.1x | Net Cash |
| Q4 2019 | -29.1x | Net Cash |
MSTR's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
ASTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 11.9 | Oversold |
ASTS's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
MSTR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.4 | Neutral |
| Stochastic | 42.1 | Neutral |
MSTR's weekly RSI is 42 (neutral) and its Stochastic is 42 (neutral).
ASTS PE vs Technology Sector
ASTS has no meaningful PE right now: it lost money over the past year.
MSTR PE vs Technology Sector
| Metric | MSTR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
MSTR has no meaningful PE right now: it lost money over the past year.
ASTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 23% below |
| 20 week MA | $57.1 | 40% below |
| 50 week MA | $75.5 | 54% below |
| 100 week MA | $57.8 | 40% below |
| 200 week MA | $33.6 | 2.8% above |
ASTS has the edge over MSTR on trend strength, trading above more of its moving averages.
MSTR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $141.2 | 19% below |
| 20 week MA | $123.6 | 7.4% below |
| 50 week MA | $138.1 | 17% below |
| 100 week MA | $235.9 | 52% below |
| 200 week MA | $168.2 | 32% below |
MSTR is in a downtrend: it's below all five of its weekly moving averages, and 32% below its 200-week average.
ASTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.87 | $13.4 | +36% |
| 2021 | $13.4 | $8.71 | -35% |
| 2022 | $8.71 | $3.97 | -54% |
| 2023 | $3.97 | $6.03 | +52% |
| 2024 | $6.03 | $22.9 | +280% |
| 2025 | $22.9 | $72.0 | +214% |
| 2026 YTD | $72.0 | $34.5 | -52% |
ASTS's yearly returns have swung widely, from +280% in 2024 to −54% in 2022. It's down 52% so far in 2026.
MSTR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.5 | $32.3 | +123% |
| 2021 | $32.3 | $59.7 | +85% |
| 2022 | $59.7 | $16.3 | -73% |
| 2023 | $16.3 | $63.2 | +288% |
| 2024 | $63.2 | $330.0 | +422% |
| 2025 | $330.0 | $158.8 | -52% |
| 2026 YTD | $158.8 | $114.4 | -28% |
MSTR has the edge over ASTS on returns for 2026, with the stronger performance.